Starting point
MAY 2007
Foundation of DR Healthcare in Barcelona (Spain), starts of its activities
MAR 2009
Presentation hypothesis of histamine/migraine at CSIC (Superior Scientific Research Council of Spain)
NOV 2009
Outset of the MigraDAO1 Study in the University of Barcelona
MAY 2010
Presentation of results of MigraDAO1 study in the International Day of Migraine, in the Congress of Spain, coinciding with the spanish presidency of the EU.
Year 2011
- Selected project aXelera Ernst & Young
- Launch In Vitro test DAO
- Start of 3 new clinical studies
MAR 2012
2nd award in the Annual Congress of Neurology
JULY 2012
Barcelona`s medical college stake in the capital of DR Healthcare
MAR 2013
Presentation of results of MigraDAO 2 Clinical Study in INFARMA 2013
Pilot launch of Migrasin
Presentation of the results of the study of gastrointestinal symptoms and migraine associated with DAO deficiency (Leipzig, Germany)
SEPT 2013
Presentation of results of Clinical Study MigraDAO 2 on Neurology World Congress (Vienna, Austria)
JUNE 2014
Presentation of the study of gastrointestinal symptoms and migraine associated with DAO deficiency (Jerusalem)
Actuality
MAY 2021
Associated British Foods pls (ABF) acquires DR Healthcare
MAY 2019
Presentation of new family products DAO
APR 2019
Presentation study of DAO Genetics
MAR 2019
Presentation new smart capsules DAO
FEB 2019
New DAO enzymatic production plant
JUNE 2018
Presentation studies Vegetable DAO
JAN 2018
- Publication study DAO-Migraine in Clinical Nutrition
- European Commission autorizes DAO as “Novel Food”
JUNE 2017
Low serum diamine oxidase (DAO) activity levels in patients with migraine
OCT 2016
New research project: Treatment with DAO in patients with chronic non-allergic rhinitis
APRIL 2016
Preparation of probiotic microorganisms with DAO activity
Year 2016
Launch of Migrasin and DAOfood
OCT 2015
Presentation of TDAH study at International Congress of Psychiatry in Habana (Cuba)
